DrugInfoSys

Fluocinonide (Topical)

Drug #309

Fluocinonide (Topical) is a topical corticosteroid (class of steroid hormones formed in the adrenal gland ). Fluocinonide (Topical) is used to reduce swelling or inflammation and itching of skin in conditions such as psoriasis, eczema, dermatitis, rashes, insect bites, and allergies etc.

Primary Characteristics

It is of Synthetic origin and belongs to Corticosteroid.

It belongs to Glucocorticoid agonist pharmacological group on the basis of mechanism of action and also classified in Corticosteroid Topical pharmacological group. It is also classified under Dermatological Products .

Molecular Weight: 494.5 · pKa: unionized · Solubility in Water: almost Insoluble · Solubility in Alcohol: 1 in 70 · Non-proprietary name: Fluocinonide (Topical).

Molecular structure of Fluocinonide (Topical)

Pharmacokinetics

None recorded.

Advertisement

Indications

Fluocinonide (Topical) is primarily indicated in conditions like Dermatitis, Eczema, Flexural psoriasis, Lichen planus, Lichen simplex, Lupus erythematosus, Necrobiosis lipoidica, Pruritus ANI.

Contraindications

Fluocinonide (Topical) is contraindicated in conditions like Bacterial infections, Fungal infection, Viral infection, Ulcers, Acne vulgaris, Rosacea, Perioral dermatitis.

Dosage

Fluocinonide (Topical)'s dosage details are as follows:

DoseSingle DoseFrequencyRouteInstructions
Adult Dosage
0.05 %0.05 %Topical As Required
Paediatric Dosage (20kg)
0.05 %0.05 %Topical As Required
Neonatal Dosage (3kg)
0.05 %0.05 %Topical As Required

Drug Interactions

None recorded.

Side Effects

Fluocinonide (Topical) in overdosage may give rise to further complications which include Glaucoma , Epidermal thinning , Raised intracranial pressure , Striae , Adrenal suppression , Cataract, Growth retardation , Telangiectasia.

Fluocinonide (Topical) is known to cause more or less tolerable side effects which are usually transient. These include Allergic reactions, Perioral dermatitis.

Warnings / Precautions

Fluocinonide should be used with caution in patients with active tuberculosis infection of respiratory tract or in untreated fungal, bacterial or systemic viral infections. Corticosteroids should only be used systemically with great caution in the presence of congestive heart failure (CHF), recent myocardial infraction (MI), hypertension, diabetes mellitus, epilepsy, glaucoma, hypothyroidism, liver failure, osteoporosis, peptic ulceration or renal impairment. Children may be at increase risk of some adverse effects, corticosteroid causes growth retardation and prolonged use is rarely justified. Passive immunization is recommended to non-immune patients who do come in contact with chickenpox or measles. Live vaccine should not be given to patients receiving high dose systemic corticosteroid therapy nor for atleast 3months afterwards, killed vaccine or toxoids may be given, although the response may be attenuated. During prolong treatment with corticosteroids, patients should be examined regularly, sodium intake may need to be reduced and calcium and potassium supplement may be necessary. Patient should carry cards given full details of their corticosteroid therapy. Avoid use during pregnancy. Use nasal steroids with caution until healing has occurred.

Interference in Pathology

Fluocinonide (Topical) may interfere in the diagnosis of ACTH Stimulation test, Urinary free cortisol test, ACTH stimulation test.

Available Brands

None recorded.

Storage Conditions

Fluocinonide (Topical) should be stored Topical Soln, Cream, Oint, Gel.

Drug Classification

  1. 1.13.3.1Corticosteroids plain